-
Zylox-Tonbridge Medical Technology Secures Licensing Deal with Avinger to Boost Device Portfolio
•
Zylox-Tonbridge Medical Technology (HKG: 2190), a China-based developer of nerve and peripheral vascular interventional devices, has announced a series of licensing and investment agreements with U.S. device manufacturer Avinger. The partnership aims to expand Zylox-Tonbridge’s portfolio of peripheral vascular intervention devices. According to the agreement, Zylox-Tonbridge will secure exclusive rights…
-
BeiGene Subsidiary Pi Health Cayman to be Merged in Deal Valued at $41.8 Million
•
BeiGene (NASDAQ: BGNE) has announced that Delaware-based Pi Health Inc. is set to absorb and merge its wholly-owned subsidiary Pi Health Cayman at a mutually agreed valuation of USD 41.8 million. Following the merger, BeiGene will directly hold the corresponding equity in Pi Health. Concurrently, Pi Health plans to bring…
-
Luye Pharma Launches Small-Cell Lung Cancer Treatment Zepzelca in Hong Kong and Macau
•
Luye Pharma Group (HKG: 2186), a China-based pharmaceutical company, has announced the official market launch of Zepzelca (lurbinectedin), a novel drug for the treatment of small-cell lung cancer (SCLC), in Hong Kong and Macau. Lurbinectedin, discovered and developed by Spain-based Pharma Mar, S.A. (MCE: PHM), is a selective inhibitor of…
-
Proviva Therapeutics Secures $18 Million in Series A Financing to Advance PTX-912
•
Proviva Therapeutics, a Shanghai-based clinical-stage biotechnology company, has reportedly secured USD 18 million in a Series A financing round led by Lapam Capital, Ennovation Ventures, and Sangel Capital. The funds raised will be directed towards the clinical advancement of the company’s core product, PTX-912. Specializing in the development of next-generation…
-
US Senate Committee Backs Bill to Restrict Chinese Biotechnology Firms’ Access to American Genetic Data
•
The U.S. Senate’s homeland security committee has voted 11-1 in favor of the Prohibiting Foreign Access to American Genetic Information Act of 2024, a bill that seeks to curb the operations of Chinese research service providers, including BGI and WuXi AppTec (SHA: 603259, HKG: 2359), within the U.S. The legislation,…
-
CARsgen Launches BCMA-Targeted CAR-T Therapy in China with High Price Point
•
China-based CAR-T cell therapy specialist CARsgen Therapeutics Holdings Ltd. (HKG: 2171) has launched its BCMA-targeted CAR-T cell therapy, CT053 (zevorcabtagene autoleucel; zevor-cel), with a price tag of RMB 1.15 million (USD 160,000), as reported by The Paper, a local media outlet. The company anticipates that the drug’s annual end sales…
-
Xian Janssen’s Tremfya Heads for Priority Review in China for Crohn’s Disease Treatment
•
The Center for Drug Evaluation (CDE) has indicated that Xian Janssen Pharmaceutical’s Tremfya (guselkumab), an IL-23 monoclonal antibody, is set to undergo priority review for the treatment of moderate to severe active Crohn’s disease (CD). The drug, which previously received breakthrough therapy designation (BTD) status, is already approved for use…
-
EMA Reviews J&J’s Darzalex Subcutaneous Formulation for Newly Diagnosed Multiple Myeloma
•
The European Medicines Agency (EMA) has this week received an indication extension filing from Johnson & Johnson (J&J; NYSE: JNJ) for a subcutaneous formulation of its anti-CD38 drug Darzalex (daratumumab). The filing seeks approval for the combination therapy with bortezomib, lenalidomide, and dexamethasone as a treatment for newly diagnosed multiple…
